Skip to Content
COVID-19 Response and Update

Strengthening Our Injectables Capabilities

We’re building a leading injectables business and have directed meaningful investments toward the growth of our injectables R&D and production capabilities, most recently through the November 3, 2021 acquisition of Puniska Healthcare, now part of Amneal Pharmaceutical Pvt Ltd.

With this transaction, we substantially expanded our injectables footprint by adding Puniska’s newly constructed 293,000 square feet, state-of-the-art manufacturing facility (located near Ahmedabad, India) to our global production network.

The world-class facility is designed to meet the highest level of regulatory compliance standards, including US FDA, EUGMP, UKMHRA and includes five sterile injectable production lines. Advanced production capabilities include robotic filling, emulsion, aseptic and lyophilization across large- and small-volume parenterals, vials and bags, enabling the production of Analgesics, Anesthetics, Antiemetics, and Anti-infectives.

Alongside these impressive production capabilities, we also elevated our sterile product R&D horsepower with more than 60 deeply experienced scientists working within Puniska’s 10,000 square-foot state-of-the-art center. The team brings expertise in pre-formulation development, formulation development, reformulation, stability studies, pre-clinical & clinical supplies, process development and optimization, plotting and scale-up validations.

Added together, we are proud of this strengthened capability which is enabling us to advance the delivery of life-saving injectable products for key markets including the U.S. and ultimately EU, LATAM and other regions of world.